/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer
S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

OncLive® On Air · Oct 7, 2026

Atibimetinib plus modified chemotherapy shows promising survival and improved tolerability in metastatic pancreatic cancer.

Short Half-Life MEK Inhibitors Prevent CRAF Bypass Resistance and Reduce Normal Tissue Toxicity

Earlier MEK inhibitors caused severe mucositis and gastrointestinal toxicities without survival benefit due to continuous pathway inhibition. Atibimetinib features a short two- to three-hour half-life that inhibits MEK and ERK phosphorylation without triggering CRAF-driven bypass resistance. Crucially, the transient drug exposure allows normal cells time to reset, substantially improving tolerability compared to prior continuous-dosing regimens.

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer thumbnail

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

OncLive® On Air·a month ago

Third-Generation MEK Inhibitor Atibimetinib Reverses Cancer Cachexia in Metastatic Pancreatic Patients

Pancreatic cancer patients frequently suffer from cancer cachexia and progressive weight loss. Early clinical trial data with atibimetinib showed that patients actually experienced weight gain alongside improved quality of life. Pairing atibimetinib with a biweekly chemotherapy regimen focuses on controlling tumor growth while maintaining patient functional status, which is vital given the incurable nature of metastatic disease.

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer thumbnail

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

OncLive® On Air·a month ago

Atibimetinib Doubles Expected Survival When Paired with Biweekly Chemotherapy in Pancreatic Cancer

Standard biweekly gemcitabine and nab-paclitaxel typically yields an expected median overall survival of approximately eight months and an 18% response rate. In a 55-patient Phase II trial across 20 sites, adding atibimetinib to this biweekly schedule produced a median overall survival of 17.3 months and a 36% overall response rate while maintaining a manageable safety profile.

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer thumbnail

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

OncLive® On Air·a month ago